We now report for the first time that the small molecule specific CBP/β-catenin antagonist ICG-001 suppresses activation of PSCs as evidenced by their decreased proliferation, down-regulation of activation markers, e.g., Acta2 (in imPSC but apparently not in ihPSC), Col1a1, Prolyl 4-hydroxylase, and Survivin, up-regulation of Ppar-γ which is associated with quiescence, and reduced migration of PSC, as well as by reduced PSC-induced migration of pancreatic cancer cells. Here, BIRC5 is linked to pancreatic neoplasm.